143 related articles for article (PubMed ID: 32893953)
1. VIVA (vinorelbine, ifosfamide, vincristine, actinomycin-D): A new regimen in the armamentarium of systemic therapy for high-risk rhabdomyosarcoma.
Ferrari A; Chiaravalli S; Zecca M; Recupero S; Pascale S; Bergamaschi L; Casanova M
Pediatr Blood Cancer; 2020 Nov; 67(11):e28649. PubMed ID: 32893953
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
3. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
[TBL] [Abstract][Full Text] [Related]
4. Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.
Kojima Y; Hashimoto K; Ando M; Yonemori K; Yamamoto H; Kodaira M; Yunokawa M; Shimizu C; Tamura K; Hosono A; Makimoto A; Fujiwara Y
Cancer Chemother Pharmacol; 2012 Sep; 70(3):391-7. PubMed ID: 22806306
[TBL] [Abstract][Full Text] [Related]
5. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
[TBL] [Abstract][Full Text] [Related]
6. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study.
Arndt C; Tefft M; Gehan E; Anderson J; Jenson M; Link M; Donaldson S; Breneman J; Wiener E; Webber B; Maurer H
J Pediatr Hematol Oncol; 1997; 19(2):124-9. PubMed ID: 9149741
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
[TBL] [Abstract][Full Text] [Related]
8. Multiagent chemotherapy including IrIVA regimen and maintenance therapy in the treatment of desmoplastic small round cell tumor.
Ferrari A; Bergamaschi L; Chiaravalli S; Pecori E; Diletto B; Alessandro O; Giandini T; Livellara V; Sironi G; Casanova M
Tumori; 2022 Feb; 108(1):93-97. PubMed ID: 33594944
[TBL] [Abstract][Full Text] [Related]
9. The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
Bisogno G; Ferrari A; Bergeron C; Scagnellato A; Prete A; Alaggio R; Casanova M; D'Angelo P; Di Cataldo A; Carli M
Cancer; 2005 Apr; 103(8):1719-24. PubMed ID: 15754335
[TBL] [Abstract][Full Text] [Related]
10. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Gupta AA; Anderson JR; Pappo AS; Spunt SL; Dasgupta R; Indelicato DJ; Hawkins DS
Cancer; 2012 Feb; 118(4):1130-7. PubMed ID: 21761400
[TBL] [Abstract][Full Text] [Related]
11. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
[TBL] [Abstract][Full Text] [Related]
12. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
Flamant F; Rodary C; Rey A; Praquin MT; Sommelet D; Quintana E; Theobald S; Brunat-Mentigny M; Otten J; Voûte PA; Habrand JL; Martelli H; Barrett A; Terrier-Lacombe MJ; Oberlin O
Eur J Cancer; 1998 Jun; 34(7):1050-62. PubMed ID: 9849454
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Rhabdomyosarcoma: Results of the European
Schoot RA; Chisholm JC; Casanova M; Minard-Colin V; Geoerger B; Cameron AL; Coppadoro B; Zanetti I; Orbach D; Kelsey A; Rogers T; Guizani C; Elze M; Ben-Arush M; McHugh K; van Rijn RR; Ferman S; Gallego S; Ferrari A; Jenney M; Bisogno G; Merks JHM
J Clin Oncol; 2022 Nov; 40(32):3730-3740. PubMed ID: 35709412
[TBL] [Abstract][Full Text] [Related]
14. Treatment of rhabdomyosarcoma and other malignant mesenchymal tumours of childhood with ifosfamide + vincristine + dactinomycin (IVA) as front-line therapy (a SIOP study).
Otten J; Flamant F; Rodary C; Brunat-Mentigny M; Dutou L; Olive D; Quintana E; Voûte PA
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S30. PubMed ID: 2667788
[No Abstract] [Full Text] [Related]
15. Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma.
Sulis ML; Bessmertny O; Granowetter L; Weiner M; Kelly KM
J Pediatr Hematol Oncol; 2004 Dec; 26(12):843-6. PubMed ID: 15591910
[TBL] [Abstract][Full Text] [Related]
16. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center.
Ortega JA; Donaldson SS; Ivy SP; Pappo A; Maurer HM
Cancer; 1997 Jun; 79(12):2435-9. PubMed ID: 9191535
[TBL] [Abstract][Full Text] [Related]
17. Replacing actinomycin-D with Carboplatin for newly diagnosed rhabdomyosarcoma.
Sezgin G; Acipayam C; Bayram I; Ozkan A; Kupeli S; Tanyeli A
Asian Pac J Cancer Prev; 2015; 16(8):3351-4. PubMed ID: 25921143
[TBL] [Abstract][Full Text] [Related]
18. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
19. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
Winter S; Fasola S; Brisse H; Mosseri V; Orbach D
Pediatr Blood Cancer; 2015 Nov; 62(11):1935-41. PubMed ID: 26150380
[TBL] [Abstract][Full Text] [Related]
20. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
